<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03770845</url>
  </required_header>
  <id_info>
    <org_study_id>NUTRIPF</org_study_id>
    <nct_id>NCT03770845</nct_id>
  </id_info>
  <brief_title>Nutritional Assessment in Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>NUTRIPF</acronym>
  <official_title>Nutritional Assessment in Idiopathic Pulmonary Fibrosis: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>San Gerardo Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>San Gerardo Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In recent years nutritional status assumed increasing importance in the evaluation of chronic
      respiratory diseases, considering that their clinical course is often characterized by a
      progressive loss of weight and reduction of muscle mass.In regards to Idiopathic Pulmonary
      Fibrosis (IPF), to date there are no studies that fully assessed the nutritional status of
      patients, nor the impact of the introduction of specific anti-fibrotic agents on the
      nutritional status of these patients.

      Aim of this study is to assess the nutritional status of patients with IPF at the time of
      diagnosis and the impact of the introduction of specific anti-fibrotic agents, pirfenidone or
      nintedanib, on the nutritional status itself.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preliminary studies on Idiopathic Pulmonary Fibrosis (IPF) seem to suggest that nutritional
      status has an impact on clinical outcomes, as already demonstrated in COPD. However, few data
      regarding this subject are available for patients with IPF.

      Primary aim of this study is to assess the nutritional status of patients diagnosed with mild
      to moderate IPF at the time of disease diagnosis. To do so, the investigators assess the
      prevalence of nutritional disorders at baseline through nutritional scores evaluated with
      specific questionnaires and through the identification of the following metabolic phenotypes
      (based on those previously applied in COPD): cachexia, sarcopenia, normal nutritional status,
      obesity, sarcopenic obesity.

      Secondary aims of this study are:

        -  the evaluation of the impact of the introduction of an anti-fibrotic pharmacological
           agent (pirfenidone or nintedanib) on the nutritional status of patients (modification of
           metabolic phenotypes and nutritional scores) evaluated at 6 months from the initiation
           of antifibrotic therapy.

        -  the assessment of calcium and vitamin D metabolism, by blood sampling, in patients
           diagnosed with mild to moderate IPF at the time of disease diagnosis and at 6 months
           from the initiation of antifibrotic therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BMI (body mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FFMI (fat free mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SMI (skeletal muscle mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>BFMI (body fat mass index)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hand Grip</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abdominal circumference</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Malnutrition Universal Screening Tool (MUST) Screening Tool (MUST)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>questionnaire score: score 0 = low risk of malnutrition; score 1 = medium risk of malnutrition; score equal or higher than 2 = high risk of malnutrition</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mini Nutritional Assessment (MNA)</measure>
    <time_frame>baseline (IPF diagnosis)</time_frame>
    <description>questionnaire score (maximum score 30): total score &gt; 23.5 = normal nutritional status; total score &lt; 23.5 = inadequate nutritional status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMI (body mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFMI (fat free mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SMI (skeletal muscle mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BFMI (body fat mass index)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg/m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand Grip</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal circumference</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malnutrition Universal Screening Tool (MUST)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>questionnaire score: score 0 = low risk of malnutrition; score 1 = medium risk of malnutrition; score equal or higher than 2 = high risk of malnutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini Nutritional Assessment (MNA)</measure>
    <time_frame>6 months after baseline</time_frame>
    <description>questionnaire score (maximum score 30): total score &gt; 23.5 = normal nutritional status; total score &lt; 23.5 = inadequate nutritional status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma calcium</measure>
    <time_frame>baseline (IPF diagnosis) and 6 months after baseline</time_frame>
    <description>calcium level in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma vitamin D</measure>
    <time_frame>baseline (IPF diagnosis) and 6 months after baseline</time_frame>
    <description>vitamin D level in plasma</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of mild to moderate Idiopathic Pulmonary Fibrosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age greater than or equal to 18 years;

          -  diagnosis of IPF according to the ATS / ERS 2011 guidelines with multidisciplinary
             discussion

        Exclusion Criteria:

          -  severe renal failure, defined as a GFR (glomerular filtration rate) lower than 30ml /
             min;

          -  NYHA class IV;

          -  severe liver failure, defined as Child-Pugh score class C;

          -  active solid or haematological neoplasms;

          -  having already received (currently or in the past) therapy with pirfenidone or
             nintedanib;

          -  inability to walk without help;

          -  need for oxygen therapy at rest;

          -  participation in other interventional experimental protocols with use of a medicinal
             product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>INRCA Casatenovo</name>
      <address>
        <city>Casatenovo</city>
        <state>Lecco</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessia Fumagalli</last_name>
      <phone>03992321</phone>
      <email>A.FUMAGALLI@inrca.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Faverio, MD</last_name>
      <phone>+39 039233</phone>
      <phone_ext>9040</phone_ext>
      <email>paola.faverio@unimib.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>G. Salvini Hospital</name>
      <address>
        <city>Garbagnate Milanese</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Bini</last_name>
      <phone>02994301</phone>
      <email>francesco_bini@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Circolo</name>
      <address>
        <city>Busto Arsizio</city>
        <state>Varese</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giulia Suigo</last_name>
      <phone>0331699111</phone>
      <email>giusuigo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Annunziata</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Marinari</last_name>
      <phone>08713571</phone>
      <email>marinaristefano@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Martino Hospital</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela Barisione</last_name>
      <phone>0105551</phone>
      <email>emanuela.barisione@hsanmartino.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Giuseppe Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Harari</last_name>
      <phone>0285991</phone>
      <email>sergio@sergioharari.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Paolo and San Carlo Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Mondoni</last_name>
      <phone>0281841</phone>
      <email>michele.mondoni@asst-santipaolocarlo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Novara</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberta Nicali</last_name>
      <phone>03213731</phone>
      <email>roberta.nicali@libero.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 6, 2018</study_first_submitted>
  <study_first_submitted_qc>December 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2018</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>San Gerardo Hospital</investigator_affiliation>
    <investigator_full_name>Paola Faverio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nutritional status</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

